|
Chlorhexidine Gluconate Topical Solution
DEFINITION
Chlorhexidine Gluconate Topical Solution is prepared from Chlorhexidine Gluconate Solution. It contains NLT 90.0% and NMT 110.0% of the labeled amount of chlorhexidine gluconate (C22H30Cl2N10·2C6H12O7).
IDENTIFICATION
• A.
The retention time of the major peak for chlorhexidine from the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
• B. Thin-Layer Chromatographic Identification Test
Standard solution:
10 mg/mL of USP Potassium Gluconate RS
Sample solution:
Nominally 20 mg/mL of chlorhexidine gluconate from the Topical Solution
Adsorbent:
0.25-mm layer of chromatographic silica gel
Application volume:
10 µL
Developing solvent system:
Alcohol, ethyl acetate, ammonium hydroxide, and water (5:1:1:3)
Spray reagent:
Dissolve 2.5 g of ammonium molybdate in 50 mL of 2 N sulfuric acid in a 100-mL volumetric flask. Add 1.0 g of ceric sulfate, swirl to dissolve, and dilute with 2 N sulfuric acid to volume.
Analysis
Samples:
Standard solution and Sample solution
Develop the chromatogram in a solvent system until the solvent front has moved 10 cm from the point of spotting. Remove the plate from the chamber, and dry at 110
Acceptance criteria:
The principal spot from the Sample solution corresponds in color, size, and RF value to that from the Standard solution.
ASSAY
• Procedure
Solution A:
Dissolve 27.6 g of monobasic sodium phosphate and 10 mL of triethylamine in 1.5 L of water. Adjust with phosphoric acid to a pH of 3.0, and dilute with water to 2000 mL. Prepare a mixture of the resulting solution and acetonitrile (70:30).
Solution B:
Acetonitrile
Mobile phase:
See the gradient table below.
System suitability solution:
50 µg/mL of USP Chlorhexidine Acetate RS and 1 µg/mL of USP p-Chloroaniline RS in Solution A
Standard solution:
50 µg/mL of USP Chlorhexidine Acetate RS in Solution A.
Sample solution:
Nominally about 80 µg/mL of chlorhexidine gluconate from the Topical Solution, prepared as follows. Transfer an amount of Topical Solution, equivalent to 40 mg of chlorhexidine gluconate, to a 100-mL volumetric flask, and dilute with methanol to volume. Further dilute a 10-mL portion of this solution with Solution A to 50 mL.
Chromatographic system
Mode:
LC
Detector:
UV 239 nm
Column:
4.6-mm × 25-cm; 5-µm packing L1
Column temperature:
40
Flow rate:
1.5 mL/min
Injection size:
50 µL
System suitability
Sample:
System suitability solution
[NoteThe approximate relative retention times for chlorhexidine and p-chloroaniline are about 1.0 and 1.3, respectively. ]
Suitability requirements
Resolution:
NLT 3.0 between chlorhexidine and p-chloroaniline
Relative standard deviation:
NMT 2.0% for the chlorhexidine peak, NMT 5.0% for the p-chloroaniline peak
Analysis
Samples:
Standard solution and Sample solution
Calculate the percentage of C22H30Cl2N10·2C6H12O7 in the portion of Topical Solution taken:
Result = (rU/rS) × (CS/CU) × (Mr1/Mr2) × 100
Acceptance criteria:
90.0%110.0%
IMPURITIES
Organic Impurities
• Procedure: Limit of p-Chloroaniline
Solution A, Solution B, Mobile phase, System suitability solution, and Chromatographic system:
Proceed as directed in the Assay.
Standard solution:
1.0 µg/mL of USP p-Chloroaniline RS in Solution A
Sample solution:
Nominally 0.4 mg/mL of chlorhexidine gluconate from the Topical Solution, prepared as follows. Transfer an amount of Topical Solution, equivalent to 40 mg of chlorhexidine gluconate, to a 100-mL volumetric flask, and dilute with Solution A to volume.
Analysis
Samples:
Standard solution and Sample solution
Acceptance criteria
The p-chloroaniline peak area from the Sample solution is NMT the p-chloroaniline peak area from the Standard solution (equivalent to NMT 500 ppm in the portion of Chlorhexidine Gluconate Solution used to prepare the Topical Solution).
SPECIFIC TESTS
• pH
ADDITIONAL REQUIREMENTS
• Packaging and Storage:
Preserve in well-closed containers, protected from light. Store at controlled room temperature.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 2626
Pharmacopeial Forum: Volume No. 36(1) Page 90
|